Citizens raised the firm’s price target on Precigen (PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm is impressed by the strength of the PAPZIMEOS launch, which reflects the strong clinical profile of the product, thorough commercial readiness activities and compelling launch execution, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN:
